- WHO released new guidance on 23 September 2026 to broaden evidence-based contraceptive choices.
- It supports extended or continuous combined oral contraceptive use, longer implant use and mifepristone as an additional emergency-contraception option.
- Implementation in India depends on national approval, product availability, programme policy and individual clinical assessment.
Geneva, 23 September 2026: The World Health Organization has issued new guidance aimed at expanding safe and effective contraceptive choices. The update covers alternative use of existing methods, emergency contraception, longer implant duration and future male contraceptive development.
What is new?
WHO states that combined oral contraceptive pills may be used for extended periods of up to six months or continuously for up to one year as alternatives to conventional cyclical use. It also supports contraceptive implant use for up to five years, potentially reducing replacement procedures and clinic visits.
The guidance recommends mifepristone as an additional emergency-contraception option when taken as soon as possible and within five days of unprotected intercourse. WHO reviewed doses of 10–50 mg and found them likely to be as safe and effective as other emergency methods.
Why this matters
WHO estimates that about 164 million women who wish to delay or avoid pregnancy are not using contraception. Greater choice may improve access and continuation because no single method suits every person.
What doctors and patients should know
- This is a population-level evidence guideline, not an individual prescription.
- Method choice still requires assessment of contraindications, pregnancy possibility, drug interactions, bleeding pattern, breastfeeding status and patient preference.
- Emergency contraception does not terminate an established pregnancy and does not protect against sexually transmitted infections.
- Condoms remain important for STI risk reduction.
Evidence limits and uncertainties
WHO calls for more research on ormeloxifene before inclusion in family-planning programmes because safety evidence remains limited. It recommends against adding quinestrol-containing contraceptive pills to national programmes because of limited evidence and reports of serious adverse events.
WHO also published its first target product profile for new male contraceptives. These products remain investigational; estimates suggesting availability within 5–10 years are projections, not approvals or guaranteed launch dates.
India-specific caveat
WHO recommendations do not automatically change Indian product approvals, national programme procurement or local prescribing protocols. Clinicians should verify CDSCO-approved labelling, MoHFW guidance and the actual product information before use.
What is known
The recommendations are based on WHO’s evidence review and were released on 23 September 2026. They expand possible approaches to existing methods and identify priority areas for future contraceptive development.
Official source
WHO news release: WHO expands safe options for contraception
Related reading
Medication Safety at Transitions of Care
Last reviewed: 23 September 2026. Educational information only; it does not replace consultation with a qualified clinician or local protocol.